SOURCE: Proteonomix, Inc.

Proteonomix, Inc.

April 28, 2009 12:46 ET

Proteonomix, Inc. (PROT) Announces Execution of Engagement Letter With Howrey LLP, an International Intellectual Property Law Firm

MOUNTAINSIDE, NJ--(Marketwire - April 28, 2009) - Proteonomix, Inc. (PINKSHEETS: PROT) announced today that it has retained the law firm of Howrey LLP to represent it and its subsidiaries in connection with intellectual property matters. Howrey LLP has nine U.S. offices, including offices in New York and Washington, and six offices in Asia and Europe. Howrey employs 275 IP professionals, of whom more than 160 have a technical background and 30 have earned a PhD. Howrey boasts Europe's premier group of IP attorneys with more than 50 professionals in centers including Amsterdam, Brussels, London, Madrid, Munich and Paris. Howrey has recently opened an Asian office in Taiwan.

Janelle D. Waack, the attorney who will be handling much of Proteonomix's matters, has practiced as a patent attorney and has been involved in numerous biotech intellectual property matters, both for corporations and universities.

Michael Cohen, President of Proteonomix, said, "We are extremely pleased to have Howrey LLP representing us as we move forward with our patent applications, both existing and in the future. Howrey has an excellent reputation and we believe we could not have made a better selection of patent counsel to represent us. Its large number of intellectual property attorneys and support staff will ensure that our intellectual matters will be addressed even more expeditiously and thoroughly than in the past. Given the marketing of our stem cell derived cosmeceutical in the Pacific Rim, we are delighted with Howrey's presence in the region."

Janelle Waack indicated that Howrey is pleased to have Proteonomix and its subsidiaries as a new client, and looks forward to a long and rewarding working relationship. Ms. Waack stated, "Howrey will take a proactive approach in protecting and managing Proteonomix' intellectual property rights, and is dedicated to the growth and success of this innovative company."

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. For more information, please visit or or

"Safe Harbor"

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto, may not occur.

Contact Information

  • Contact:
    Michael Cohen
    Proteonomix, Inc.
    (973) 544-6116
    Email Contact